ArticleVirulence2020
Article in Virulence, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 43 citations in OpenAlex.
- Rethinking Mycoplasma hyopneumoniae adhesion: a glycocalyx-mediated infectious niche model in porcine respiratory infection.Veterinary research · 2026Review
- Genomic Characterization of aVeterinary sciences · 2026Article
- Clinical Presentation, Detection, and Immunopathogenesis ofPathogens (Basel, Switzerland) · 2026Article
- Review
- The grand escape - how pathogens outsmart the human complement system.Immunobiology · 2025Review
- Role of P38 lipoprotein in Mycoplasma penetrans adhesion to human urothelial cells.BMC microbiology · 2025Article
- Unraveling the role of distinct cytoskeletal motility structures in Mycoplasma pneumoniae relatives.BMC microbiology · 2025Review
- MreB: unraveling the molecular mechanisms of bacterial shape, division, and environmental adaptation.Cell communication and signaling : CCS · 2025Review
- Whole-Genome Sequencing of Blood-Isolated Lactobacillus johnsonii in Thailand: Clinical Implications and Public Health Relevance.The American journal of case reports · 2025Article
- The Pathogenomics of the RespiratoryPathogens (Basel, Switzerland) · 2025Article
- Advances in adhesion-related pathogenesis inFrontiers in microbiology · 2025Review
- Use of Subtherapeutic Tylvalosin AgainstTransboundary and emerging diseases · 2025Article
- Pathogenic mechanisms and vaccine development forFrontiers in microbiology · 2025Review
- Pseudomonas aeruginosa elongation factor-Tu (EF-Tu) is an immunogenic protective protein antigen.Vaccine · 2024Article
- Screening inhibitors against the Ef-Tu of Fusobacterium nucleatum: a docking, ADMET and PBPK assessment study.Molecular diversity · 2024Article
- HylS', a fragment of truncated hyaluronidase ofVirulence · 2024Article
- Research Progress on Immune Evasion ofMicroorganisms · 2024Review
- Exploring the pathogenetic mechanisms ofExperimental and therapeutic medicine · 2024Review
- A genetic and virulence characterization of Brazilian strains ofFrontiers in microbiology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasmas persist in the host for a long time, suggesting that they possess mechanisms for immune evasion. Factor H is a negative regulator of the complement system, which binds to host cells to avoid unexpected complement activation. In this study, we revealed that many mycoplasmas, such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.